Long-Term Treatment of VTE: Case Studies

Slides:

Advertisements

Similar presentations

Oral rivaroxaban alone for the treatment of symptomatic pulmonary embolism: the EINSTEIN PE study Harry R Büller on behalf of the EINSTEIN Investigators.

Advertisements

The EINSTEIN PE Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Pulmonary Embolism.

Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.

The EINSTEIN DVT Study 'Xarelto' for the Acute and Continued Treatment of Symptomatic Deep Vein Thrombosis.

EINSTEIN DVT and EINSTEIN PE Pooled Analysis

The EINSTEIN EXT Study 'Xarelto' for the Long-Term Prevention of Recurrent Venous Thromboembolism.

Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.

H.R. Buller, G. Agnelli Presented at the XXIst Congress of International Society on Thrombosis and Haemostasis (ISTH) 2007 Meeting, July 6-12th in Geneva,

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,

Outpatient DVT assessment & treatment Daniel Gilada.

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.

Ryan Sparks, PharmD, BCPS PGY2 Cardiology Resident

Clinical Professor in Palliative Medicine

NOACs for Cancer-Associated Thrombosis:

Extended Treatment of VTE: Who is the Right Candidate?

NOACs In Long-term VTE Treatment: A State Of The Art Review

Thrombosis, Cancer, and NOACs

NOACs in Clinical Practice: Are They All the Same?

New Strategies to Prevent CV Events After Hospital Discharge

Emergency Management of NOAC Bleeding

A New Era for NOACs:.

POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Statin Selection in Special Patient Populations: A Case Challenge

Before and After: Patient Cases in Onychomycosis

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

How to Adjust Anticoagulant Dosing

New Oral Anticoagulants and VTE Management

Real-World Safety of NOACs: What Do We Know Today?

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Adherence in SPAF: Measures to Improve Care

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Real-World Evidence in VTE

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

APEX: Primary Efficacy and Safety Results

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

First-Line FCR: Effect of del(17p) on PFS and OS

Improving Adherence to Antiplatelet Therapy After an ACS Event

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

How to Adjust Anticoagulant Dosing

Treating Pulmonary Embolism Today

Presentation transcript:

Long-Term Treatment of VTE: Case Studies

Program Goals

VTE Acute, Long-Term, and Extended Treatment

Case 1 Unprovoked DVT

Case Comments

How Long to Treat?

Other Factors to Consider

Case 2 Postoperative PE

Case 3 75 Year Old With PE and DVT

NOAC Dosing in Renal Dysfunction: US Labeling

EINSTEIN CHOICE Study Design

EINSTEIN CHOICE Primary Outcome—Recurrent VTE

EINSTEIN CHOICE Bleeding Outcomes

AMPLIFY-EXT Efficacy and Safety

Who Requires Extended Therapy?

EINSTEIN CHOICE and EINSTEIN-Extension Recurrent VTE by Risk Factor of Index Event

EINSTEIN CHOICE Effect on Clinical Practice

Transition of Care

Ensuring Adherence

Abbreviations